OR5B17 Inhibitors
OR5B17 inhibitors represent a specialized class of chemical compounds that target and modulate the activity of the OR5B17 receptor, a member of the olfactory receptor family. Olfactory receptors, traditionally associated with the detection of odorants in the nasal cavity, are G-protein-coupled receptors (GPCRs) that play a key role in chemosensation. OR5B17, like other olfactory receptors, functions by binding specific ligands, leading to conformational changes that trigger intracellular signaling pathways. The binding of an inhibitor to OR5B17 specifically interferes with this process, typically by preventing the receptor from engaging with its natural ligands, thus modulating the downstream signaling events initiated by this interaction. The specificity of OR5B17 inhibitors lies in their structural complementarity to the receptor's binding domain, where they often mimic or competitively block access to the binding sites, preventing the receptor from activating the signal transduction pathways that would normally follow ligand binding.
Structurally, OR5B17 inhibitors are designed to interact with the highly conserved transmembrane domains of the GPCR framework, which form the core of the receptor's ligand-binding region. These inhibitors often exhibit a diversity of functional groups that enhance their binding affinity through interactions such as hydrogen bonding, hydrophobic interactions, and Van der Waals forces. By focusing on the molecular topology of OR5B17, chemists can design inhibitors that precisely target this receptor, allowing for controlled modulation of its activity. Additionally, the chemical diversity of these inhibitors opens the door to extensive research into their mechanisms of action, receptor selectivity, and structural optimization for efficient receptor interaction. In the context of chemical biology, OR5B17 inhibitors serve as important molecular tools for probing the structure-function relationships of olfactory receptors and for exploring the biochemical pathways influenced by these GPCRs.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent could induce demethylation of cytosine bases within the promoter region of the OR5B17 gene, potentially leading to a decrease in the transcriptional activity of OR5B17 by altering the binding affinity of transcriptional repressors. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine may lead to the hypomethylation of the OR5B17 gene promoter, which might suppress its expression by disrupting the recruitment of methyl-CpG-binding domain proteins that promote transcriptional silencing. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, could directly keep histones in a hyperacetylated state, thereby reducing the transcriptional activity of the OR5B17 gene by maintaining the chromatin in a condensed, transcriptionally inactive configuration. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid might downregulate OR5B17 expression by hyperacetylating histones in the vicinity of the gene, leading to the suppression of transcription factor assembly on the OR5B17 promoter. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A could bind to specific DNA sequences upstream of the OR5B17 gene, obstructing the binding sites for transcriptional activators and thus decreasing OR5B17 gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D may intercalate into DNA strands within the OR5B17 gene, thereby blocking the progression of RNA polymerase and leading to a decrease in OR5B17 mRNA synthesis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid could downregulate OR5B17 expression by binding to retinoic acid receptors that heterodimerize with repressor proteins bound to the OR5B17 promoter, leading to repression of the gene's transcription. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate might reduce OR5B17 expression by inhibiting the synthesis of purine nucleotides, thereby depleting the building blocks necessary for the transcription of the OR5B17 gene. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could decrease OR5B17 expression by specifically inhibiting the mTOR signaling pathway, which may be crucial for the translation of OR5B17 mRNA into the functional receptor protein, leading to a reduction in the overall levels of OR5B17. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib might specifically inhibit the epidermal growth factor receptor (EGFR) tyrosine kinase, which could result in the downregulation of a cascade that includes transcription factors responsible for the enhanced transcription of the OR5B17 gene. | ||||||